Dendreon: Provenge to Survive Health Reform

Dendreon(DNDN Quote) shares fell Wednesday after a column in the New York Times suggested that cuts to expensive prostate cancer treatments must be made if the U.S. is to reform its bloated and expensive health care system.

However, the column by New York Times economics writer David Leonhardt focused on men with early-stage prostate cancer. Doctors will use Dendreon's Provenge to treat men with advanced prostate cancer. Current treatment options for these men offer little hope for long-term survival.

Nonetheless, Dendreon fell more than 5% to $22.66 Wednesday. The stock fell as much as 8% intraday. ...